↓ Skip to main content

Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry

Overview of attention for article published in Clinical Rheumatology, July 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)
  • High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

news
2 news outlets

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
17 Mendeley
Title
Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry
Published in
Clinical Rheumatology, July 2017
DOI 10.1007/s10067-017-3742-2
Pubmed ID
Authors

Leslie R. Harrold, Ani John, Jennie Best, Steve Zlotnick, Chitra Karki, YouFu Li, Jeffrey D. Greenberg, Joel M. Kremer

Abstract

To evaluate the impact of rituximab on patient-reported outcomes (PROs) in a US-based observational cohort of patients with rheumatoid arthritis (RA). Patients with active RA, prior exposure to ≥1 tumor necrosis factor inhibitor (TNFi) and who newly initiated rituximab were identified. Changes in PROs were assessed 1 year after rituximab initiation. PRO measures included Clinical Disease Activity Index (CDAI); patient global disease activity, pain and fatigue (visual analog score; 0-100); morning stiffness (hours); modified Health Assessment Questionnaire (mHAQ; 0-3); and EuroQoL EQ-5D. Of the 667 patients who newly initiated rituximab, baseline PRO and clinical measures indicated that patients were substantially impacted by their RA disease and quality of life; 54% of patients had high disease activity. One year after rituximab initiation, 49.0, 47.1, 49.8, and 23.2% of patients reported clinically meaningful improvements in patient global, pain, fatigue, and mHAQ, respectively. Morning stiffness and EuroQol EQ-5D domains improved in 48 and 19-32% of patients, respectively. These real-world registry data demonstrated that patients with long-standing, refractory RA experienced improvements in PROs 1 year after initiating rituximab.

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 17 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 24%
Researcher 4 24%
Student > Doctoral Student 3 18%
Other 2 12%
Student > Postgraduate 1 6%
Other 3 18%
Readers by discipline Count As %
Medicine and Dentistry 11 65%
Unspecified 2 12%
Pharmacology, Toxicology and Pharmaceutical Science 2 12%
Social Sciences 1 6%
Engineering 1 6%
Other 0 0%

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 July 2017.
All research outputs
#820,070
of 11,527,700 outputs
Outputs from Clinical Rheumatology
#60
of 1,379 outputs
Outputs of similar age
#34,668
of 262,167 outputs
Outputs of similar age from Clinical Rheumatology
#7
of 46 outputs
Altmetric has tracked 11,527,700 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,379 research outputs from this source. They receive a mean Attention Score of 4.6. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,167 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 46 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.